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Results:
There were twenty-one patients in the historic control group.
The total cost of the hospital admissions was $AUD1,771,448
(average $AUD84,354, range $AUD28,856-276,989). Total phar-
maceutical costs for all 21 patients was $AUD 798,583, represent-
ing 45% of total costs.
Twenty (95%) patients in the historical group experienced mu-
cositis with 48% having grade 3 or 4. All ﬁve patients who received
palifermin experienced mucositis but no patients had grade 3 or 4.
The average number of TPN days was 8.3 days (median 9.5 days)
in the control group compared to 12.2 days (median 9.0 days) in
palifermin recipients. Patients that received palifermin had a mean
LOS of 34.4 days (median 25 days) compared to mean of 36.5 days
(median 35) for the control group.
Conclusion:
Palifermin usage was associated with a decreased incidence and
severity of oral mucositis with a reduction in LOS, antibiotic and
antifungal costs. Further validation of these results is required in a
larger cohort of patients.
Impact of Degree of Mucositis and Usage of Palifermin
Historical
Contol
(n21)
Palifermin
treated
group
(n5)
Mucositis any Grade - mean
days duraton
14 8
Mucositis Grade 3 or 4 -
mean days duration
3.3 0
Mucositis grade 3 or 4 - pts
(%)
11 (52.4) 0 (0)
TPN usage - mean days
duration
8 12.2
TPN usage - median days
duration
9.5 9.0
Duration of hospitalisation -
mean days
36.5 34.4
Duration of hospitalisation -
median days
35.0 25.0
Antifungal usage - mean
$AUD
$15,728 $12,854
Antifungal usage - median
$AUD
$10,720 $2,389
Total cost antibiotics,
antifungals, TPN - mean
$AUD
$20,929 $18,811
Total cost antibiotics,
antifungals, TPN -
median $AUD
$15,553 $5,605
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Background: The impact of oral mucositis associated with au-
tologous stem cell transplantation (SCT) following high dose che-
motherapy and radiotherapy has been evaluated in the clinical trial
setting to assess the effects of palifermin. The impact of palifermin
in the allogenic peripheral blood (PBSCT) and TBI and the costs
associated has not been quantiﬁed.
Aim:
To perform an analysis of the costs associated with allogenic
PBSCT in patients who received TBI and assess the impact of oral
mucositis and palifermin.
Method:
The costs associated with patients undergoing allogenic PBSCT
and TBI following high dose chemotherapy were quantiﬁed. Consec-
utive patients who received palifermin (Oct 05-July 06) and a control
group (June 04-Oct 05) that had not were included. Costs were
determined through data extracts from the hospital’s clinical costing
system and through retrospective medical record review. Incidence,
duration and grade of mucositis, length of hospital stay (LOS), anti-
infective use and requirements for total parenteral nutrition (TPN)
were quantiﬁed.
Results:
There were eleven patients in the historic control group and ten
(91%) experienced mucositis. Five patients were evaluated in the
palifermin group and all experience mucositis. The average number of
days of oral mucositis was 8.0 days in the palifermin group compared
to 17 days in the control group. None of the palifermin treated
patients experienced grade 3 or 4 mucositis compared to 73% in the
control group who had an average duration of Grade 3-4 mucositis of
8 days (median 6 days). Patients that received palifermin had a mean
LOS of 34.4 days (median 25.0 days) compared to mean of 36.5 days
(median 28) for the control group. The average number of TPN days
with palifermin recipients was 12.2 days (median 9.0 days) compared
to 8 days (median 9 days) in the control group. For one patient who
received palifermin, TPN usage (37 days) was indicated for severe
nausea rather thanmucositis. The total costs of antibiotics, antifungals
and TPN during the period of hospitalisation was on average
$AUD18,811 (median $AUD5,606) for those patients who received
palifermin compared to $AUD18,324 (median $AUD$8,856) for
those that did not .
Conclusion:
Palifermin usage was associated with a substantial decreased
incidence and severity of oral mucositis with a reduction in LOS in
patients who received TBI with allogenic PBSCT. Further valida-
tion of these results is required in a larger cohort of patients.
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ROLE OF TRANSFUSION IN STEM CELL TRANSPLANTATION: A FREE-
DOM-FROM-TRANSFUSION (FFT), COST AND SURVIVAL ANALYSIS
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Introduction: Transfusion of blood products is often an integral
part of stem cell transplantation (SCT). Little literature exists to
deﬁne the impact of transfusion on the outcome of SCT.
Methods: In an attempt to evaluate the need and volume of
transfusion in patients undergoing SCT in our institution, we
retrospectively evaluated the records of all patients who received
SCT from 1995 till 2000.
Results:Out of 210 patients, 154 patients received autologous SCT
and 56 patients received allogeneic SCT between 1995 and 2000.
Non-Hodgkin’s lymphoma (53%) and leukemia (73%) were the most
frequent indications for autologous and allogeneic SCT respectively.
Peripheral blood stem cell (PBSC) was used in all but one patient
undergoing autologous SCT. Fifty patients received PBSC and 16
patients received bone marrow as the source of stem cells during
allogeneic SCT. One hundred thirty eight (90%) out of 154 patients
undergoing autologous SCT and 24 (43%) out of 56 patients with
allogeneic SCT exhibited total hematopoietic engraftment and free-
dom from transfusion (FFT). Time to achieve FFT in days (median;
range) for RBC units for autologous SCT (12; 0-183) was signiﬁcantly
shorter compared with allogeneic SCT (16.5; 0-373). Number of
RBC units (median; range) transfused were less in patients undergoing
autologous SCT (4; 0-26) compared with patients undergoing allo-
geneic SCT (6.5; 0-54). The median cost of transfusion was signiﬁ-
cantly higher in patients undergoing allogeneic transplantation (Red
cell: $2015; and Platelet: $4480) compared to patients undergoing
autologous transplantation (Red cell: $1240 and Platelet: $2520). The
number of transfused RBC and platelet units negatively correlated
with overall survival (median duration of follow-up: 1.3 years) in
patients with autologous SCT, but not in patients with allogeneic
SCT. This signiﬁcance remained valid in both continuous regression
analysis by Cox and dichotomous analysis (above and below median
number of transfused units) by Kaplan-Meier.
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